用户名: 密码: 验证码:
Preventive effect of pidotimod on reactivated toxoplasmosis in mice
详细信息    查看全文
  • 作者:Xing-Xing Huo (1) (2) (3)
    Lin Wang (1)
    Zhao-Wu Chen (4)
    He Chen (1) (2)
    Xiu-Cai Xu (4)
    Ai-Mei Zhang (4)
    Xiao-Rong Song (4)
    Qing-Li Luo (1)
    Yuan-Hong Xu (2)
    Yu Fu (1) (4)
    Hua Wang (1)
    Jian Du (1)
    Yi-Hong Cai (1)
    Zhao-Rong Lun (5)
    Fang-Li Lu (5)
    Yong Wang (6)
    Ji-Long Shen (1) (7)
  • 刊名:Parasitology Research
  • 出版年:2013
  • 出版时间:August 2013
  • 年:2013
  • 卷:112
  • 期:8
  • 页码:3041-3051
  • 全文大小:807KB
  • 参考文献:1. Adams K, Allen JA, Brooker PC, Henderson L, Jones E, Proudlock RJ, Mailland F, Coppi G (1994) Genotoxicity testing of pidotimod in vitro and in vivo. Drug Res (Stuttg) 44(12A):1454-459
    2. Barragan A, Sibley LD (2002) Transepithelial migration of / Toxoplasma gondii is linked to parasite motility and virulence. J Exp Med 195(12):1625-633 CrossRef
    3. Chiarenza A, Iurato MP, Barbera N, Lempereur L, Cantarella G, Scapagnini U, Bernardini R (1994) Modulating effects of the synthetic thymic dipeptide pidotimod on the immune system in the aging rat. Pharmacol Toxicol 74(4-):262-66 CrossRef
    4. Coppi G, Amico-Roxas M, Berte F, Bussi R, Gnemi P, Harling RJ, Mailland F, Manzardo S, Massey JE, Spencer-Briggs DJ et al (1994) Toxicological evaluation of pidotimod. Drug Res (Stuttg) 44(12A):1448-453
    5. Cortez E, Stumbo AC, Oliveira M, Barbosa HS, Carvalho L (2009) Statins inhibit / Toxoplasma gondii multiplication in macrophages in vitro. Int J Antimicrob Agents 33(2):185-86 CrossRef
    6. Dellacasa-Lindberg I, Hitziger N, Barragan A (2007) Localized recrudescence of / Toxoplasma infections in the central nervous system of immunocompromised mice assessed by in vivo bioluminescence imaging. Microbes Infect 9(11):1291-298 CrossRef
    7. Di Renzo M, Pasqui AL, Bruni F, Saletti M, Bova G, Chiarion C, Girardello R, Ferri P, Auteri A (1997) The in vitro effect of pidotimod on some immune functions in cancer patients. Immunopharmacol Immunotoxicol 19(1):37-1 CrossRef
    8. Du XF, Jiang CZ, Wu CF, Won EK, Choung SY (2008) Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression. Arch Pharm Res 31(9):1153-159 CrossRef
    9. Frawley R, White K Jr, Brown R, Musgrove D, Walker N, Germolec D (2011) Gene expression alterations in immune system pathways in the thymus after exposure to immunosuppressive chemicals. Environ Health Perspect 119(3):371-76 CrossRef
    10. Gazzinelli R, Xu Y, Hieny S, Cheever A, Sher A (1992) Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with / Toxoplasma gondii. J Immunol 149(1):175-80
    11. Gazzinelli RT, Eltoum I, Wynn TA, Sher A (1993) Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J Immunol 151(7):3672-681
    12. Gharavi MJ, Jalali S, Khademvatan S, Heydari S (2011) Detection of IgM and IgG anti- / Toxoplasma antibodies in renal transplant recipients using ELFA, ELISA and ISAGA methods: comparison of pre- and post-transplantation status. Ann Trop Med Parasitol 105(5):367-71 CrossRef
    13. Giagulli C, Noerder M, Avolio M, Becker PD, Fiorentini S, Guzman CA, Caruso A (2009) Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. Int Immunopharmacol 9(12):1366-373 CrossRef
    14. Giampietri A, Bonmassar E, Goldin A (1978) Drug induced modulation of immune responses in mice: effects of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) and cyclophosphamide (Cy). J Immunopharmacol 1(1):61-6 CrossRef
    15. Guiton R, Vasseur V, Charron S, Arias MT, Van Langendonck N, Buzoni-Gatel D, Ryffel B, Dimier-Poisson I (2010) Interleukin 17 receptor signaling is deleterious during / Toxoplasma gondii infection in susceptible BL6 mice. J Infect Dis 202(3):427-35 CrossRef
    16. Ho IC, Vorhees P, Marin N, Oakley BK, Tsai SF, Orkin SH, Leiden JM (1991) Human GATA-3: a lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene. EMBO J 10(5):1187-192
    17. Israelski DM, Remington JS (1993) Toxoplasmosis in patients with cancer. Clin Infect Dis 17(Suppl 2):S423–S435 CrossRef
    18. Jensen KD, Wang Y, Wojno ED, Shastri AJ, Hu K, Cornel L, Boedec E, Ong YC, Chien YH, Hunter CA, Boothroyd JC, Saeij JP (2011) Toxoplasma polymorphic effectors determine macrophage polarization and intestinal inflammation. Cell Host Microbe 9(6):472-83 CrossRef
    19. Jost C, Reiter-Owona I, Liesenfeld O (2007) The timing of sulfadiazine therapy impacts the reactivation of latent / Toxoplasma infection in IRF-8??/sup> mice. Parasitol Res 101(6):1603-609 CrossRef
    20. Katlama C, De Wit S, O’Doherty E, Van Glabeke M, Clumeck N (1996) Pyrimethamine–clindamycin vs. pyrimethamine–sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 22(2):268-75 CrossRef
    21. Kelly MN, Kolls JK, Happel K, Schwartzman JD, Schwarzenberger P, Combe C, Moretto M, Khan IA (2005) Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against / Toxoplasma gondii infection. Infect Immun 73(1):617-21 CrossRef
    22. Lachenmaier SM, Deli MA, Meissner M, Liesenfeld O (2011) Intracellular transport of / Toxoplasma gondii through the blood–brain barrier. J Neuroimmunol 232(1-):119-30 CrossRef
    23. Manzardo S, Falcone A, Pinzetta A, Ieva G, Coppi G (1994) General pharmacology of pidotimod and testing for drug interactions. Drug Res (Stuttg) 44(12A):1441-447
    24. Mazur L, Czyzewska A, Bochenek M (2002) Flow cytometric detection of apoptotic bone marrow cells with fractional DNA content after application of WR-2721, cyclophosphamide, cisplatin, and exposure of mice to gamma rays. Hum Exp Toxicol 21(6):335-41 CrossRef
    25. Mehlhorn H, Dankert W, Hartman PG, Then RL (1995) A pilot study on the efficacy of epiroprim against developmental stages of / Toxoplasma gondii and / Pneumocystis carinii in animal models. Parasitol Res 81(4):296-01 CrossRef
    26. Meneceur P, Bouldouyre MA, Aubert D, Villena I, Menotti J, Sauvage V, Garin JF, Derouin F (2008) In vitro susceptibility of various genotypic strains of / Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother 52(4):1269-277 CrossRef
    27. Migliorati G, Coppi G, D’Adamio F, Pagliacci C, Nicoletti I, Riccardi C (1992) Immunopharmacology of pidotimod: effect on natural killer cell activity and thymocyte cell death. Pharmacol Res 26(Suppl 2):154-55 CrossRef
    28. Migliorati G, Nicoletti I, Riccardi C (1994) Immunomodulating activity of pidotimod. Drug Res (Stuttg) 44(12A):1421-424
    29. Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet 363(9425):1965-976 CrossRef
    30. Scholer N, Krause K, Kayser O, Muller RH, Borner K, Hahn H, Liesenfeld O (2001) Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 45(6):1771-779 CrossRef
    31. Silva NM, Vieira JC, Carneiro CM, Tafuri WL (2009) / Toxoplasma gondii: the role of IFN-gamma, TNFRp55 and iNOS in inflammatory changes during infection. Exp Parasitol 123(1):65-2 CrossRef
    32. Song X, Shen J, Wen H, Zhong Z, Luo Q, Chu D, Qi Y, Xu Y, Wei W (2011) Impact of / Schistosoma japonicum infection on collagen-induced arthritis in DBA/1 mice: a murine model of human rheumatoid arthritis. PLoS One 6(8):e23453 CrossRef
    33. Sumyuen MH, Garin YJ, Derouin F (1996) Effect of immunosuppressive drug regimens on acute and chronic murine toxoplasmosis. Parasitol Res 82(8):681-86 CrossRef
    34. Suzuki Y, Joh K, Kwon OC, Yang Q, Conley FK, Remington JS (1994) MHC class I gene(s) in the D/L region but not the TNF-alpha gene determines development of toxoplasmic encephalitis in mice. J Immunol 153(10):4649-654
    35. Xavier GA, Cademartori BG, Cunha Filho NA, Farias NA (2013) Evaluation of seroepidemiological toxoplasmosis in HIV/AIDS patients in the south of Brazil. Rev Inst Med Trop Sao Paulo 55(1):25-0 CrossRef
    36. Yang X, Huang B, Chen J, Huang S, Zheng H, Lun ZR, Shen J, Wang Y, Lu F (2012) In vitro effects of aqueous extracts of / Astragalus membranaceus and / Scutellaria baicalensis Georgi on / Toxoplasma gondii. Parasitol Res 110(6):2221-227 CrossRef
    37. Yoshida H, Miyazaki Y, Wang S, Hamano S (2007) Regulation of defense responses against protozoan infection by interleukin-27 and related cytokines. J Biomed Biotechnol 2007(3):79401
    38. Zhao Q, Zhang M, Hong L, Zhou K, Lin Y (2010) Evaluation of drug effects on / Toxoplasma gondii nuclear and plastid DNA replication using real-time PCR. Parasitol Res 106(5):1257-262 CrossRef
  • 作者单位:Xing-Xing Huo (1) (2) (3)
    Lin Wang (1)
    Zhao-Wu Chen (4)
    He Chen (1) (2)
    Xiu-Cai Xu (4)
    Ai-Mei Zhang (4)
    Xiao-Rong Song (4)
    Qing-Li Luo (1)
    Yuan-Hong Xu (2)
    Yu Fu (1) (4)
    Hua Wang (1)
    Jian Du (1)
    Yi-Hong Cai (1)
    Zhao-Rong Lun (5)
    Fang-Li Lu (5)
    Yong Wang (6)
    Ji-Long Shen (1) (7)

    1. The Key Laboratories of Parasitology and Zoonoses Anhui and Department of Parasitology, Anhui Medical University, Hefei, 230032, People’s Republic of China
    2. Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People’s Republic of China
    3. Clinical Laboratory Center, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, 230031, People’s Republic of China
    4. Anhui Provincial Hospital, Hefei, 230001, People’s Republic of China
    5. State Key Laboratory of Biocontrol, School of Life Sciences, Key Laboratory of Tropical Diseases Control, The Ministry of Education, and The Department of Parasitology, Zhongshan Medical College, Sun Yat-Sen (Zhongshan) University, Guangzhou, 510275, People’s Republic of China
    6. Department of Pathogen Biology, Nanjing Medical University, Nanjing, 210029, People’s Republic of China
    7. Institute of Zoonoses and Parasitology, Anhui Medical University, No. 81, Meishan Road, Hefei, 230032, People’s Republic of China
文摘
As one of food-borne parasitic diseases, toxoplasmosis entails the risk of developing reactivation in immunocompromised patients. The synthetic dipeptide pidotimod is a potent immunostimulating agent that improves the immunodefenses in immunodepression. To investigate the efficacy of pidotimod as a preventive treatment, we used a murine model of reactivated toxoplasmosis with cyclophosphamide (CY)-induced immunosuppression. Pidotimod administration significantly restored the body weight and spleen organ index, increased survival time (from 70 to 90?%), and decreased the parasitemia (from 80 to 35?%) of CY-induced mice with reactivated toxoplasmosis. Cytokine profiles and CD4+ T cells subpopulation analyses by Cytometric Bead Array and flow cytometry demonstrated that pidotimod treatment resulted in a significant upregulation of pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-2) and Th1 cells (from 3.73?±-.39 to 5.88?±-.46?%) after CY induction in infected mice. Additionally, histological findings and parasite DNA quantification revealed that mice administered with pidotimod had a remarkable reduction of parasite burden (two-log) and amelioration of histopathology in the brains. The in vitro studies showed that pidotimod significantly restored concanavalin A-induced splenocyte proliferation and pro-inflammatory cytokines in the supernatants of splenocyte culture. It could be concluded that the administration of pidotimod in immunocompromised mice significantly increases the Th1-biased immune response, prolongs survival time, and ameliorates the load of parasites in the blood. This is the first report of the preventive effect of pidotimod on reactivated toxoplasmosis.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700